

Application Serial No.: 09/918,187
DOCKET NO.: ISPH-0590 (4042.3007 US)

PATENT

AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions and listing of claims in the instant application:

1. (Currently Amended) An antisense oligonucleotide ~~compound~~ 20 12 to 30 nucleobases in length comprising at least one modified nucleobase targeted to a nucleic acid molecule encoding human stearyl-CoA deasaturase (SEQ ID NO: 3), wherein said antisense oligonucleotide ~~compound~~ specifically hybridizes to SEQ ID NO: 3 with 100% complementarity and ~~with said nucleic acid molecule encoding human stearyl-CoA deasaturase,~~ comprises at least an 8-nucleobase portion of SEQ ID NO: 30, ~~and inhibits the expression of stearyl-CoA deasaturase by at least 10%.~~

2-3 (Canceled)

4. (Currently Amended) The antisense oligonucleotide compound of claim 1 wherein the antisense oligonucleotide comprises at least one modified internucleoside linkage.

5. (Currently Amended) The antisense oligonucleotide compound of claim 4 wherein the modified internucleoside linkage is a phosphorothioate linkage.

6. (Currently Amended) The antisense oligonucleotide compound of claim 1 wherein the antisense oligonucleotide comprises at least one modified sugar moiety.

7. (Currently Amended) The antisense oligonucleotide compound of claim 6 wherein the modified sugar moiety is a 2'-O-methoxyethyl sugar moiety.

8. (Canceled)

9. (Currently Amended) The antisense oligonucleotide compound of claim 1 wherein the modified nucleobase is a 5-methylcytosine.

10. (Currently Amended) The antisense oligonucleotide compound of claim 1 wherein the antisense oligonucleotide is a chimeric oligonucleotide.

11. (Canceled)

Application Serial No.: 09/918,187
DOCKET NO.: ISPH-0590 (4042.3007 US)

PATENT

12. (Currently Amended) A composition comprising the antisense oligonucleotide compound of claim 1 and a pharmaceutically acceptable carrier or diluent.

13. (Original) The composition of claim 12 further comprising a colloidal dispersion system.

14-27 (Canceled)

28. (Currently Amended) A method of inhibiting the expression of human stearyl-CoA desaturase in cells or tissues comprising contacting the cells or tissues in vitro with the antisense oligonucleotide compound of claim 1 so that expression of human stearyl-CoA desaturase is inhibited.